If you purchased Seagen Inc. securities and would like to join the action, please click "Join This Action" below.
SGEN STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF SEAGEN INC. IS FAIR TO SHAREHOLDERS
March 13, 2023.
New York, New York—Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Seagen Inc. (NASDAQ: SGEN) to Pfizer Inc. for $229.00 in cash per share is fair to Seagen shareholders.
The investigation concerns whether Seagen and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Seagen shareholders; (2) determine whether Pfizer is underpaying for Seagen; and (3) disclose all material information necessary for Seagen shareholders to adequately assess and value the merger consideration. On behalf of Seagen shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.